Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Aclaris Therapeutics to Participate in Two March Healthcare Conferences
-
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
-
New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3
-
Aclaris Therapeutics announces formation of new scientific advisory board
-
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
-
Aclaris Therapeutics Announces $80 Million Private Placement
-
Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline
-
Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update